

18 May 2021

Australian Securities Exchange
20 Bridge Street,
Sydney NSW 2000

Change of Directors' Holdings

Highlights:

- Ms Rebecca Wilson (Alcidion Chair) has acquired 15,327 shares in the recently completed SPP
- Ms Robyn Morris (spouse of NED Raymond Blight) has acquired 93,750 shares in the SPP
- MKMS Investment Trust has sold 11.48 million shares during the current trading window
- MKMS Investment Trust, owned by the former owners of MKM Health which was acquired by Alcidion in 2018, is being dissolved following the share sale
- Mr Simon Chamberlain (NED) has acquired 295,000 shares as part of the MKMS disposal

Melbourne, Australia – Alcidion Group Limited (ASX: ALC) board has today been advised of a change in shareholding by several directors, two of whom are substantial shareholders.

MKMS Investment Pty Ltd <MKMS Investment Trust> (MKMS) has sold all the 11.48 million ALC shares that it held through a broker managed on-market transaction. The sale of shares was undertaken at \$0.34 per share.

MKMS is an entity owned by the five former owners of MKM Health to manage MKM Health's investment in Patientrack, both of which were acquired by Alcidion in 2018. MKMS is no longer an appropriate investment vehicle for the individual parties involved and is therefore being dissolved, requiring the sale of its interest in Alcidion. The unit holders of MKMS include current and retired employees of Alcidion, who each continue to hold significant individual shareholdings in Alcidion. Kate Quirke's interest in MKMS equated to 1,497,557 million shares, representing approximately 3% of her shareholding. Ms Quirke retains a cumulative total of 46,561,285 shares.

Simon Chamberlain, a non-executive director, has acquired 295,000 shares at \$0.34 as part of the MKMS managed sale.

Ms Rebecca Wilson and Ms Robyn Morris (spouse of NED Raymond Blight) subscribed for further shares in the SPP, receiving 15,327 and 93,750 shares, respectively after having their original applications scaled back in a manner consistent with other SPP applicants. Ms Wilson now holds 1,517,924 shares in Alcidion.

In accordance with the ASX listing rules, relevant change in Director and Substantial Shareholder disclosures will be released as appropriate.

Rebecca Wilson, Alcidion Chair said, "The sale of MKMS shares to Simon Chamberlain along with several institutional shareholders further reflects the strong underlying support for Alcidion and assists in maintaining an orderly market as the MKMS structure is dissolved. All of the underlying unit holders in MKMS remain significant shareholders in Alcidion, with everyone excited by the growth opportunities that lie ahead".

ENDS

For further information, please contact:



Kyahn Williamson

WE Communications

Ph: +61 401 018 828

kwilliamson@we-worldwide.com

About Alcidion Group Limited (ASX: ALC)

Alcidion Group Limited (Alcidion) has a simple purpose: to transform healthcare with proactive, smart, intuitive technology solutions that improve the efficiency and quality of patient care in healthcare organisations, worldwide.

Alcidion offers a complementary set of software products and technical services that create a unique offering in the global healthcare market. Based on the flagship product, Miya Precision, the solutions aggregate meaningful information to centralised dashboards, support interoperability, facilitate communication and task management in clinical and operational settings and deliver Clinical Decision Support at the point of care; all in support of Alcidion's mission to improve patient outcomes.

Since listing on the ASX in 2011, Alcidion has acquired multiple healthcare IT companies and expanded its foothold in the UK, Australia, and New Zealand to now service over 300 hospitals and 60 healthcare organisations, with further geographical expansion planned.

With over 20 years of healthcare experience, Alcidion brings together the very best in technology and market knowledge to deliver solutions that make healthcare better for everyone.

www.alcidion.com

© Alcidion Group Limited 2021. Alcidion, Miya Precision, Patientrack and Smartpage are registered trademarks. All other brands and product names and trademarks are the registered property of their respective companies.

This announcement is authorised for release by the Board of Directors of Alcidion Group Limited.

For personal use only

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	ALCIDION GROUP LIMITED
ABN	77 143 142 410

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Katrina Elizabeth Doyle (aka Kate Quirke)
Date of last notice	23 November 2020

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct & Indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	MNMD Pty Ltd <Quirke Superannuation Fund> (Sole Director and Beneficiary) (MNMD) MKMS Investment Pty Ltd <MKMS Investment Trust> (Director and Unit Holder) (MKMS)* Robin Michael Doyle <The Doyle Super Fund> (Joint Trustee) (RMD)
Date of change	17 May 2021
No. of securities held prior to change	Direct 27,793,199 Fully Paid Ordinary Shares 2,547,511 Performance Rights expiring 31.10.2023 Indirect 18,668,086 Fully Paid Ordinary Shares (MNMD) 100,000 Fully Paid Ordinary Shares (RMD) 11,481,273 Fully Paid Ordinary Shares (MKMS)
Class	Fully Paid Ordinary Shares
Number acquired	-
Number disposed	11,481,273* <i>Katrina Doyle's beneficial interest in ALC shares held by MKMS is 1,497,557 shares.</i>

*Katrina Elizabeth Doyle's beneficial interest in ALC shares held by MKMS equates to 13% of MKMS's total holding

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y
Change of Director's Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$3,903,632.82 (\$0.34 per share) <i>The value of Katrina Doyle's beneficial interest ALC shares disposed of by MKMS was \$509,169.38.</i>
No. of securities held after change	Direct 27,793,199 Fully Paid Ordinary Shares 2,547,511 Performance Rights expiring 31.10.2023 Indirect 18,668,086 Fully Paid Ordinary Shares (MNMD) 100,000 Fully Paid Ordinary Shares (RMD)
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	On-market trade

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	ALCIDION GROUP LIMITED
ABN	77 143 142 410

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Raymond Howard Blight
Date of last notice	28 August 2019

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct & Indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Ms Robyn Gaile Morris (Spouse of Mr Raymond Blight)
Date of change	11 May 2021
No. of securities held prior to change	Direct 96,028,781 Fully Paid Ordinary Shares Indirect 4,549,300 Fully Paid Ordinary Shares
Class	Fully Paid Ordinary Shares
Number acquired	Indirect 93,750 Fully Paid Ordinary Shares
Number disposed	-
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	\$0.32 per share

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y
Change of Director's Interest Notice

No. of securities held after change	Direct 96,028,781 Fully Paid Ordinary Shares Indirect 4,643,050 Fully Paid Ordinary Shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issued pursuant to Share Purchase Plan announced on 15 April 2021

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	ALCIDION GROUP LIMITED
ABN	77 143 142 410

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Rebecca Wilson
Date of last notice	12 March 2020

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct & Indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Parker and Wilson Investment Pty Ltd <Parker & Wilson Superannuation Fund> (Director and Beneficiary)
Date of change	11 May 2021
No. of securities held prior to change	Direct 570,000 Fully Paid Ordinary Shares Indirect 910,000 Fully Paid Ordinary Shares
Class	Fully Paid Ordinary Shares
Number acquired	Direct 15,327 Fully Paid Ordinary Shares Indirect 22,597 Fully Paid Ordinary Shares
Number disposed	-
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	\$12,135.68

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y
Change of Director's Interest Notice

No. of securities held after change	Direct 585,327 Fully Paid Ordinary Shares Indirect 932,597 Fully Paid Ordinary Shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issued pursuant to Share Purchase Plan announced on 15 April 2021

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.

For personal use only

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	ALCIDION GROUP LIMITED
ABN	77 143 142 410

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Simon Chamberlain
Date of last notice	1 July 2019

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Bright Ventures Super Pty Ltd <Bright Ventures S/F A/C>
Date of change	17 May 2021
No. of securities held prior to change	-
Class	Fully Paid Ordinary Shares
Number acquired	Indirect 295,000 Fully Paid Ordinary Shares
Number disposed	-
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	\$100,300
No. of securities held after change	Indirect 295,000 Fully Paid Ordinary Shares
Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	On-market trade

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y Change of Director's Interest Notice

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.

For personal use only